WP 809
Latest Information Update: 24 Apr 2002
Price :
$50 *
At a glance
- Originator Nonindustrial source
- Class Antineoplastics
- Mechanism of Action DNA cross linking agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 14 Mar 2000 New profile
- 14 Mar 2000 Preclinical development for Cancer in USA (Unknown route)